reports
- ABGSC Energy Research
- John Olaisen
- Oliver Dunvold
- Stian Wibstad
Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase...
Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase-IIb-Studie HARMONY in Vorträgen und Postern auf dem EASL-Kongress 2025 Die Analyse der Ergebnisse zu EFX mit KI-basierter digitaler Pathologie unterstreicht den potenziellen Wert bei der Bewertung des histopathologischen Ansprechens Die Daten tragen dazu bei, dass die antifibrotische Wirkung von EFX bei Patienten mit präzirrhotischer MASH immer deutlicher wird SOUTH SAN FRANCISCO, Kalifornien, May 11, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein im klinischen Stadium tätiges Unternehmen, das ...
Akero Therapeutics et HistoIndex présentent de nouvelles analyses de l...
Akero Therapeutics et HistoIndex présentent de nouvelles analyses de l’essai de phase IIb HARMONY lors de présentations orales et d’affiches lors du congrès 2025 de l’EASL L’analyse des résultats de l’EFX au moyen de la pathologie numérique basée sur l’IA souligne le potentiel d’évaluation de la réponse histopathologique Ces données s’ajoutent au nombre croissant de preuves de l’activité anti-fibrotique de l’EFX chez les patients atteints de MASH pré-cirrhotique SOUTH SAN FRANCISCO, État de Californie, 11 mai 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ : AKRO), une soc...
Genius Group CEO, Roger Hamilton’s X Account Hacked
Genius Group CEO, Roger Hamilton’s X Account Hacked SINGAPORE, May 10, 2025 (GLOBE NEWSWIRE) -- (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered, Bitcoin-first education group, today announced that the X account of its CEO, Roger Hamilton (X handle: @rogerhamilton), has been compromised. The hackers posted false information without the Company’s knowledge or consent regarding an alleged token launch by the Company. Any posts, solicitations or other messages allegedly announcing this are false and must not be relied upon. The Company and Mr. Hamilton urge the ...
DAVIDsTEA Announces the Passing of Founder Herschel Segal
DAVIDsTEA Announces the Passing of Founder Herschel Segal MONTREAL, May 10, 2025 (GLOBE NEWSWIRE) -- DAVIDsTEA Inc. (TSX-Venture: DTEA) (“DAVIDsTEA” or the “Company”) announces with deep sadness the passing of its founder Herschel Segal in Montreal, Québec on Tuesday, May 6, 2025. Herschel Segal was a pioneering Canadian entrepreneur whose career shaped two iconic retail brands. He was the founder of Le Château, a fashion retailer that became a mainstay in Canadian shopping culture for decades. In 2008, he co-founded DAVIDsTEA, transforming the specialty tea category with a bold, modern ...
DAVIDsTEA annonce le décès de son fondateur Herschel Segal
DAVIDsTEA annonce le décès de son fondateur Herschel Segal MONTRÉAL, 10 mai 2025 (GLOBE NEWSWIRE) -- DAVIDsTEA Inc. (TSX-Venture : DTEA) (« DAVIDsTEA » ou la « Société ») annonce avec une profonde tristesse le décès de son fondateur, Herschel Segal, survenu à Montréal, Québec, le mardi 6 mai 2025. Herschel Segal était un entrepreneur canadien visionnaire dont la carrière a marqué deux marques emblématiques du commerce de détail. Il a fondé Le Château, un détaillant de mode devenu une référence dans la culture du magasinage au Canada pendant des décennies. En 2008, il a cofondé DAVIDsTEA,...
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnis...
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der Fibrose ohne Verschlechterung der MASH SOUTH SAN FRANCISCO, Kalifornien, May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein in der klinischen Phase tätiges Unternehmen, das bahnbrechende Therapien für Patienten mit schwerwiegenden Stoffwechselkrankheiten entwickelt, für die ein hoher medizinischer Bedarf besteht, ha...
Akero Therapeutics présente les résultats de la 96e semaine de l’essai...
Akero Therapeutics présente les résultats de la 96e semaine de l’essai clinique de phase 2b SYMMETRY sur l’éfruxifermine chez des patients atteints de cirrhose compensée causée par une stéatohépatite associée à un dysfonctionnement métabolique (MASH), montrant une amélioration de la fibrose sans aggravation de la MASH lors du congrès 2025 de l’EASL SOUTH SAN FRANCISCO, État de Californie, 10 mai 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ : AKRO), une société en phase clinique développant des traitements révolutionnaires pour les patients atteints de maladies métaboliques gr...
Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im...
Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im New England Journal of Medicine bekannt Die Ergebnisse stützen den potenziellen Nutzen von Efruxifermin (EFX) für eine Fibrosebesserung unter Patienten mit kompensierter Zirrhose (F4-Fibrose) aufgrund von MASH auf Basis von SYMMETRY-Studiendaten nach 96 Wochen, die auf dem EASL Congress 2025 präsentiert wurden SOUTH SAN FRANCISCO, Kalifornien, May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein Unternehmen für die Entwicklung wegweisender klinischer Behandlungen für Patienten mit ernstzunehme...
Akero Therapeutics annonce la publication de l’essai de phase 2b SYMME...
Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine Les résultats confirment le bénéfice potentiel de l’éfruxifermine (EFX) pour déclencher une amélioration de la fibrose chez les patients atteints de cirrhose compensée (fibrose F4) due à une MASH ; les données à 96 semaines de l’essai SYMMETRY ont fait l’objet d’une présentation lors du congrès 2025 de l’EASL SOUTH SAN FRANCISCO, État de Californie, 10 mai 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ : AKRO), une société en phase clinique développant des traiteme...
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HAR...
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUTH SAN FRANCISCO, Calif., May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic dise...
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmeti...
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk categories by year twoPatients achieved a mean 6.7 kPa reduction in liver stiffness, which was statistically significant compared to baseline CONSH...
Cascades Inc: 1 director
A director at Cascades Inc bought 12,000 shares at 8.570CAD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Open Text Corporation: 1 director
A director at Open Text Corporation sold 20,000 shares at 27.229USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Element Fleet Management Corp: 1 director
A director at Element Fleet Management Corp sold 35,000 shares at 31.504CAD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Loomis AB: 1 director
A director at Loomis AB bought 850 shares at 356.882SEK and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
AltaGas Ltd: 1 director
A director at AltaGas Ltd sold 12,500 shares at 39.132CAD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Nanjing CIGU Technology Corp Ltd: 1 director
A director at Nanjing CIGU Technology Corp Ltd sold 696,523 shares at 33.760CNY and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Turning Point Brands Inc: 3 directors
Three Directors at Turning Point Brands Inc sold/sold after exercising options 15,000 shares at between 73.640USD and 76.560USD. The significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...
Preferred Bank (Los Angeles, CA): 1 director
A director at Preferred Bank (Los Angeles, CA) sold 14,723 shares at 82.730USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.